- Home
- PASG vs FBIO Comparison
PASG vs FBIO Comparison
Compare PASG & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASG
- FBIO
- Stock Information
- Founded
- PASG 2017
- FBIO 2006
- Country
- PASG United States
- FBIO United States
- Employees
- PASG N/A
- FBIO N/A
- Industry
- PASG Biotechnology: Pharmaceutical Preparations
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PASG Health Care
- FBIO Health Care
- Exchange
- PASG Nasdaq
- FBIO Nasdaq
- Market Cap
- PASG 42.2M
- FBIO 39.4M
- IPO Year
- PASG 2020
- FBIO N/A
- Fundamental
- Price
- PASG $0.64
- FBIO $1.81
- Analyst Decision
- PASG Strong Buy
- FBIO Strong Buy
- Analyst Count
- PASG 3
- FBIO 3
- Target Price
- PASG $8.00
- FBIO $18.00
- AVG Volume (30 Days)
- PASG 1.2M
- FBIO 691.0K
- Earning Date
- PASG 11-13-2024
- FBIO 11-14-2024
- Dividend Yield
- PASG N/A
- FBIO N/A
- EPS Growth
- PASG N/A
- FBIO N/A
- EPS
- PASG N/A
- FBIO N/A
- Revenue
- PASG N/A
- FBIO $81,501,000.00
- Revenue This Year
- PASG N/A
- FBIO N/A
- Revenue Next Year
- PASG N/A
- FBIO $134.70
- P/E Ratio
- PASG N/A
- FBIO N/A
- Revenue Growth
- PASG N/A
- FBIO 31.51
- 52 Week Low
- PASG $0.45
- FBIO $1.36
- 52 Week High
- PASG $1.79
- FBIO $4.43
- Technical
- Relative Strength Index (RSI)
- PASG 48.32
- FBIO 49.60
- Support Level
- PASG $0.65
- FBIO $1.78
- Resistance Level
- PASG $0.90
- FBIO $2.27
- Average True Range (ATR)
- PASG 0.13
- FBIO 0.17
- MACD
- PASG -0.02
- FBIO -0.03
- Stochastic Oscillator
- PASG 5.73
- FBIO 21.43
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.